News

Immunotherapy Helps Myeloma Patients Who Relapse After Stem Cell Transplant, Study Shows

Many patients with blood cancers, such as myeloma, go into remission after receiving a stem-cell transplant. However, there are still many patients (about one-third) who relapse, a condition usually associated with a poor prognosis. Dana-Farber Cancer Institute researchers tested the effects of a new treatment approach using repeated doses of the immunotherapy drug Yervoy (ipilimumab), showing…

Elevated BMI Linked to Multiple Myeloma Development and Progression

A study has uncovered that elevated body mass index (BMI), a measurement of obesity, increases an individual’s risk of developing multiple myeloma and the disease’s risk of progression. The study, “Adipocytes contribute to the growth and progression of multiple myeloma: Unraveling obesity related differences in adipocyte signaling,” was recently published…

Risk of Myeloma Still Small Despite Newly Revealed Gene Mutations

In the largest study to date, researchers from The Institute of Cancer Research in London identified eight new gene mutations increasing the risk of developing myeloma — a risk that is still very small, according to experts. The study, “Genome-wide association study identifies multiple susceptibility loci for…

EU OKs Extended Indication for Amgen’s Myeloma Drug Kyprolis

Global biotech firm Amgen has announced that the European Commission (EC) approved a variation to the marketing authorization for Kyprolis (carfilzomib) to be used in combination with dexamethasone alone for adults suffering from multiple myeloma who have been treated at least once. This extended indication is the second EC approval for…

Multiple Myeloma Treatment Outcomes May Improve with ‘Next-Generation Drug Candidates’, Review Says

Advances in the molecular understanding of multiple myeloma (MM) onset and disease development have enabled the production of effective drugs, such as bortezomib,thalidomide, and lenalidomide, that increase the length of progression-free survival and prolong overall survival. While the drugs have dramatically improved the day-to-day quality of life of patients with MM,…

One Multiple Myeloma Induction Therapy Stands Out in Test for Transplant-eligible Patients

Results from a clinical trial support the use of a specific combination drug induction therapy over another three-drug treatment in multiple myeloma patients who are eligible for transplants. The study indicates the combination of bortezomib-thalidomide-dexamethasone (VTD) is a better induction therapy than bortezomib-cyclophosphamide-dexamethasone (VCD). VCD was less efficient and was associated…

Relapsed/Refractory Multiple Myeloma Drug by Takeda Receives Negative Opinion from EMA

Takeda Pharmaceutical Company Limited has recently received a negative opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), which recommended against authorizing NINLARO (ixazomib) capsules for relapsed and/or refractory multiple myeloma. Takeda plans to request a re-evaluation of the CHMP opinion. In a press release, Dr.

Multiple Myeloma Among Topics in APSHO Educational Series for Healthcare Workers

The Advanced Practitioners Society for Hematology and Oncology (APSHO) is presenting a series of live continuing medical education (CME) meetings, titled the “APSHO Regional Lecture Series.” The accredited meetings are designed for nurses, physician assistants, clinical nurse specialists, advanced degree nurse pharmacists, and others involved in caring for patients with…

New Data from Key Trial of Kyprolis to Treat Advanced Multiple Myeloma Shows Benefits

Amgen reported findings from a post-hoc analysis of the pivotal Phase 3 ASPIRE clinical trial, highlighting the continued benefits of carfilzomib (Kyprolis), a second-generation proteasome inhibitor, plus a standard two-drug regimen (lenalidomide and dexamethasone) in relapsed multiple myeloma patients. The findings were presented during the recent 21st Congress of the European Hematology Association (EHA) in Denmark. A separate sub-analyses…